Secondly, the original presentation of Table 1 contained errors in the "Europe", "Middle East", "South Africa", and "Asia" columns in the rows falling under the following row headings: "Concomitant MTX, n (%)", and "Concomitant csDMARD combinations c , n (%)". Table 1 has been corrected and is presented as follows:
The online version of the original article can be found at https://doi.org/ 10.1007/s10067-018-4074-6 * Patrick Durez patrick.durez@uclouvain.be 5.7 ± 1.0 5.9 ± 1.1 6.0 ± 1.0 6.4 ± 1.0 6.7 ± 1.1 6.2 ± 0.9 DAS28-CRP, mean ± SD 5.2 ± 1.0 5.5 ± 1.0 5.4 ± 0.9 5.8 ± 1.0 5.8 ± 1.0 5.4 ± 0.9 Disease duration (y), mean ± SD 7.5 ± 7.8 6.6 ± 8.4 6.9 ± 7.0 8.6 ± 8.2 7.6 ± 7.9 5.4 ± 4.8 TJC28, mean ± SD 11.6 ± 6.5 14.5 ± 7.5 12.6 ± 6.3 15.1 ± 6.1 15.3 ± 6.6 12.7 ± 6.1 SJC28, mean ± SD 8.3 ± 5.1 10.5 ± 4.7 7.5 ± 4.6 11.8 ± 5.7 14.1 ± 6.1 8. c Only the six combinations most commonly used by the efficacy-evaluable population for all regions combined are listed. All other combinations were used by <3% of the total efficacy-evaluable population
